Loading...

뉴스 목록

뉴스 목록

The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca
The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca

2023 The first fluorine-containing drug was approved. 2023.01.27 Eli Lilly's Loxo Oncology annou

더 읽어보세요 2023-02-01
PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials
PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials

Scientists from the University of Illinois at Urbana-Champaign and other institutes found that PAC-1

더 읽어보세요 2023-01-09
adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market
adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market

2022.12.12, the US FDA announced the approval of Mirati Therapeutics' oral KRAS G12C inhibitor a

더 읽어보세요 2022-12-15
New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!
New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel a

더 읽어보세요 2022-11-25
Huatangning, the world's first new hypoglycemic drug was approved
Huatangning, the world's first new hypoglycemic drug was approved

Beijing, Oct. 9, 2022 -- Bayer announced that the global initiative for state and drug administratio

더 읽어보세요 2022-10-09
Haihe Pharmaceuticals' Paclitaxel Oral Solution China Marketing Authorization Application Officially Accepted

On September 13, 2022, Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. and South Ko

더 읽어보세요 2022-09-14
Using artificial intelligence to detect Parkinson's disease by reading people's breathing patterns
Using artificial intelligence to detect Parkinson's disease by reading people's breathing patterns

Parkinson's disease is notoriously difficult to diagnose because it relies primarily on the onse

더 읽어보세요 2022-08-24
Targeting specific DNA of Plasmodium may be effective in treating human malaria infection
Targeting specific DNA of Plasmodium may be effective in treating human malaria infection

Targeting a parasite's DNA could be a more effective way to combat malaria, new research from th

더 읽어보세요 2022-07-28
Vijoice is the first FDA-approved PRS treatment
Vijoice is the first FDA-approved PRS treatment

2022.04.06, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelera

더 읽어보세요 2022-07-06